Clinical Laserthermia Systems AB Class B (SE:CLS.B)
:CLS.B
Want to see SE:CLS.B full AI Analyst Report?
Top Page
Clinical Laserthermia Systems AB Class B
(CLS.B)
Select Model
Select Model
Rating:46Neutral
Price Target:
kr4.00
▼(-41.09% Downside)
Action:Reiterated
Date:05/12/26
The score is primarily held down by weak financial performance—ongoing heavy losses, negative margins, and persistent cash burn—despite a relatively low-debt balance sheet. Technical indicators are mixed with only modest near-term momentum and longer-term downtrend signals. Valuation is not supportive because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Recurring revenue from consumables
CLS's device-plus-consumables model creates a durable attached revenue stream: once systems are installed, hospitals buy single-use fibers and accessories repeatedly. This recurring demand can stabilize revenue per installed unit, improve lifetime customer value, and support margin recovery as installed base grows.
Negative Factors
Persistent heavy losses and negative margins
Deep operating losses and a negative gross margin imply the business currently cannot cover product or direct costs at scale. Without a credible path to positive unit economics, continued losses will erode equity, constrain reinvestment, and make long-term competitiveness and independent sustainability highly dependent on external capital or rapid margin improvement.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring revenue from consumables
CLS's device-plus-consumables model creates a durable attached revenue stream: once systems are installed, hospitals buy single-use fibers and accessories repeatedly. This recurring demand can stabilize revenue per installed unit, improve lifetime customer value, and support margin recovery as installed base grows.
Read all positive factors
Clinical Laserthermia Systems AB Class B (CLS.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr134.17M
Dividend YieldN/A
Average Volume (3M)333.29K
Price to Earnings (P/E)―
Beta (1Y)0.50
Revenue Growth-29.16%
EPS Growth44.24%
CountrySE
Employees17
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-1.67
Shares Outstanding31,163,593
10 Day Avg. Volume370,302
30 Day Avg. Volume333,294
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.55
Price to Sales (P/S)10.18
P/FCF Ratio-4.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)kr37.70M
Clinical Laserthermia Systems AB Class B Business Overview & Revenue Model
Company Description
Clinical Laserthermia Systems AB (publ) develops treatment tools for diseased tissue under the TRANBERG brand in Sweden. The company offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. It also prov...
How the Company Makes Money
CLS generates revenue primarily by commercializing its laserthermia platform, which typically involves (1) sales of capital equipment (the laser/monitoring system installed at hospitals/clinics), (2) recurring sales of procedure-related consumable...
Clinical Laserthermia Systems AB Class B Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
20
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 17.49M | 18.78M | 8.27M | 6.27M | 2.25M |
| Gross Profit | -29.00M | 10.42M | 3.00M | -2.79M | -3.63M |
| EBITDA | -26.41M | -44.76M | -68.41M | -57.84M | -57.05M |
| Net Income | -41.61M | -47.62M | -79.79M | -70.66M | -63.62M |
Balance Sheet | |||||
| Total Assets | 76.49M | 78.56M | 57.73M | 49.51M | 66.74M |
| Cash, Cash Equivalents and Short-Term Investments | 21.55M | 22.51M | 15.33M | 10.59M | 31.17M |
| Total Debt | 0.00 | 224.00K | 454.00K | 30.68M | 273.50K |
| Total Liabilities | 10.00M | 12.88M | 14.20M | 41.64M | 45.55M |
| Stockholders Equity | 69.67M | 68.72M | 45.77M | 9.22M | 21.79M |
Cash Flow | |||||
| Free Cash Flow | -35.91M | -58.92M | -71.95M | -71.25M | -66.73M |
| Operating Cash Flow | -33.20M | -56.45M | -66.45M | -70.69M | -66.17M |
| Investing Cash Flow | -2.80M | -7.47M | -5.50M | -886.00K | -408.00K |
| Financing Cash Flow | 35.04M | 71.10M | 76.69M | 61.84M | 85.88M |
Clinical Laserthermia Systems AB Class B Technical Analysis
Neutral
6.79
Price Trends
4.61
Negative
5.90
Negative
6.86
Negative
Market Momentum
-0.10
Negative
49.32
Neutral
26.98
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CLS.B, the sentiment is Neutral. The current price of 6.79 is above the 20-day moving average (MA) of 4.20, above the 50-day MA of 4.61, and below the 200-day MA of 6.86, indicating a neutral trend. The MACD of -0.10 indicates Negative momentum. The RSI at 49.32 is Neutral, neither overbought nor oversold. The STOCH value of 26.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:CLS.B.
Clinical Laserthermia Systems AB Class B Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
69 Neutral | kr123.91M | 35.29 | ― | ― | -12.51% | -59.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr151.69M | ― | ― | ― | ― | 68.59% | |
48 Neutral | kr147.52M | -19.07 | ― | ― | 59.15% | 10.47% | |
46 Neutral | kr134.17M | -4.76 | -61.62% | ― | -29.16% | 44.24% | |
43 Neutral | kr38.26M | -2.89 | -60.56% | ― | 27.31% | 6.31% | |
41 Neutral | kr48.84M | -2.11 | -50.21% | ― | ― | -104.27% |
* Healthcare Sector Average
SE:CLS.B
Clinical Laserthermia Systems AB Class B
4.35
1.73
66.03%
SE:SPEC
SpectraCure AB
0.08
-0.12
-57.79%
SE:LXB
Luxbright AB
0.15
-0.58
-79.95%
SE:HEART
Scandinavian Real Heart AB
17.60
3.65
26.16%
SE:NOSA
Nosa Plugs AB
0.53
-0.29
-35.58%
SE:ARCOMA
Arcoma AB
9.38
-0.28
-2.90%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.